Document is current
Any future updates will be listed below
-
Authors
Lin, Benjamin
Shelton, Abigail K.
Smithberger, Erin
Ziebro, Julia
Skinner, Kasey R.
Bash, Ryan E.
Kirkman, Richard
Stamper, Allie
Butler, Madison
Flores, Alex
Angus, Steven P.
East, Michael P.
Cloughesy, Timothy F.
Nathanson, David A.
Berens, Michael E.
Sarkaria, Jann N.
Binder, Zev A.
O’Rourke, Donald M.
Howton, Timothy C.
Lasseigne, Brittany N.
Willey, Christopher D.
Johnson, Gary L.
Hjelmeland, Anita B.
Furnari, Frank B.
Miller, C. Ryan
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (T32GM008361)
National Cancer Institute (F31CA247177)
National Cancer Institute (R01CA227089)
National Cancer Institute (R01CA227089)
National Cancer Institute (R01CA204136)
National Cancer Institute (U01CA227954)
National Cancer Institute (R37CA285434)
National Cancer Institute (R01CA258248)
National Cancer Institute (R01CA258248)
National Cancer Institute (R01CA258248)
National Cancer Institute (R01CA204136)
National Cancer Institute (R01CA258248)
National Cancer Institute (R01CA258248)
National Cancer Institute (R01CA258248)
National Institute of Neurological Disorders and Stroke (R01NS121319)
National Institute of Neurological Disorders and Stroke (R01NS121319)
National Institute of Neurological Disorders and Stroke (R01NS042645)
National Institute of Neurological Disorders and Stroke (R01NS127424)
National Institute of Neurological Disorders and Stroke (R01NS080939)
National Institute of Neurological Disorders and Stroke (R01NS134798)
- License Information
-
More Information
Article History
Received: 1 May 2025
Accepted: 21 June 2025
First Online: 28 June 2025
Declarations
:
: Not applicable.
: Not applicable.
: DAN is a cofounder, major stockholder, consultant, and board member of Katmai Pharmaceuticals, co-founder and stockholder of Trethera Corporation, stockholder in Sofie Biosciences, and provides paid consulting services to Asteroid Therapeutics. TFC is cofounder, primary stock holder, consultant and board member of Katmai Pharmaceuticals, member of the board for the 501c3 Global Coalition for Adaptive Research, holds stock option of Notable Labs, holds stock in Chimerix and receives milestone payments and possible future royalties, member of the scientific advisory board for Break Through Cancer, member of the scientific advisory board for Cure Brain Cancer Foundation, has provided paid consulting services to GCAR, Jubilant, Immvira, Gan and Lee, BrainStorm, Katmai, Sapience, Inovio, Vigeo Therapeutics, DNATrix, Tyme, SDP, Novartis, Roche, Kintara, Bayer, Merck, Boehinger Ingelheim, VBL, Amgen, Kiyatec, Odonate Therapeutics QED, Medefield, Pascal Biosciences, Bayer, Tocagen, Karyopharm, GW Pharma, Abbvie, VBI, Deciphera, VBL, Agios, Genocea, Celgene, Puma, Lilly, BMS, Cortice, Wellcome Trust, Novocure, Novogen, Boston Biomedical, Sunovion, Human Longevity, Insys, ProNai, Pfizer, Notable labs, Medqia Trizel, Medscape and has contracts with UCLA for the Brain Tumor Program with Oncovir, Merck, Oncoceutics, Novartis, Amgen, Abbvie, DNAtrix, Beigene, BMS, AstraZeneca, Kazia, Agios, Boston Biomedical, Deciphera, Tocagen, Orbus, AstraZenica, Karyopharm. FBF is a cofounder and scientific advisor of Trotana Therapeutics. ZAB and DMO hold patents relating to CAR T cells, which the University of Pennsylvania licenses to Tmunity Therapeutics. DMO reports prior or active roles as a consultant/scientific advisory board member for Celldex Therapeutics, Prescient Therapeutics, and Century Therapeutics (GBM Advisory Board) and reports receiving commercially sponsored research grants from Celldex Therapeutics, Novartis, and Tmunity Therapeutics. DMO is an inventor on patent applications jointly owned by the University of Pennsylvania and Novartis. The intellectual property of DMO includes U.S patents 7,625,558, 6,417,168 and related families. DMO received royalties related to targeted ErbB therapy in solid cancers previously licensed by the University of Pennsylvania.
